Women's Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar.
Global Vascular Access LLC, Scottsdale, AZ, USA.
J Vasc Access. 2024 Jul;25(4):1229-1237. doi: 10.1177/11297298231154629. Epub 2023 Feb 16.
Evidence-based insertion and maintenance strategies for neonatal vascular access devices (VAD) exist to reduce the causes of VAD failure and complications in neonates. Peripheral intravenous catheter failure and complications including, infiltration, extravasation, phlebitis, dislodgement with/without removal, and infection are majorly influenced by catheter securement methods.
A retrospective, observational study using routinely collected data on intravenous device use in a large neonatal intensive care unit in Qatar. A 6-month historical cohort was compared with a 6-month cohort after the introduction of an octyl-butyl-cyanoacrylate glue (CG). In the historical cohort, the catheter was secured using a semi-permeable transparent membrane dressing while in the CG cohort, CG was applied at the insertion site on initial insertion and after any dressing change. This was the only variable intervention between both groups.
A total of 8330 peripheral catheters were inserted. All catheters were inserted and monitored by members of the NeoVAT team. 4457 (53.5%) were secured with just a semi-permeable transparent dressing and 3873 (46.5%) secured a semi-permeable transparent dressing with the addition of CG. The odds ratio for premature failure after securement with CG was 0.59 (0.54-0.65) when compared to the catheters secured with a semi-permeable transparent dressing, which was statistically significant ( < 0.001). The correlation between the occurrence of a complication and the use of CG for device securement was significant ( < 0.001).
The risk of developing device-related phlebitis and premature device removal, increased significantly if CG was not used for adjunct catheter securement. In parallel with the currently published literature, this study's findings support the use of CG for vascular device securement. When device securement and stabilization concerns are most pertinent CG is a safe and effective adjunct to reducing therapy failures in the neonatal patient population.
现已有循证的新生儿血管内装置(VAD)置入和维护策略,以降低 VAD 失败和新生儿并发症的原因。外周静脉导管失败和并发症,包括渗漏、外渗、静脉炎、移位(伴有/不伴有移除)和感染,主要受导管固定方法的影响。
这是一项在卡塔尔一家大型新生儿重症监护病房使用常规收集的静脉内装置使用数据进行的回顾性观察性研究。将 6 个月的历史队列与引入辛基丁基氰基丙烯酸酯胶(CG)后的 6 个月队列进行比较。在历史队列中,导管使用半透性透明膜敷料固定,而在 CG 队列中,在初始插入和每次更换敷料时,在插入部位涂抹 CG。这是两组之间唯一的变量干预。
共插入 8330 个外周导管。所有导管均由 NeoVAT 团队成员插入和监测。4457 个(53.5%)仅用半透性透明敷料固定,3873 个(46.5%)用半透性透明敷料加 CG 固定。与使用半透性透明敷料固定的导管相比,CG 固定后提前失效的优势比为 0.59(0.54-0.65),具有统计学意义(<0.001)。并发症的发生与 CG 用于设备固定之间的相关性具有统计学意义(<0.001)。
如果不使用 CG 辅助导管固定,发生设备相关性静脉炎和导管提前移除的风险显著增加。与目前已发表的文献一致,本研究结果支持使用 CG 进行血管内装置固定。当装置固定和稳定问题最为突出时,CG 是一种安全有效的辅助手段,可降低新生儿患者群体的治疗失败率。